Immunovant (IMVT) Shares Outstanding (2018 - 2026)

Immunovant has reported Shares Outstanding for 9 years, with the latest figure at $203.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 2039303.53% year-over-year to $203.9 million; the trailing twelve-month figure through Mar 2026 stood at $203.9 million (up 2039303.53% YoY), and the FY2026 full-year result was $203.9 million, up 2039303.53% from the prior year.
• Shares Outstanding for Q1 2026 stood at $203.9 million, roughly flat from $203.3 million in the prior quarter.
• The five-year high for Shares Outstanding was $203.3 million in Q4 2025, with the low at $10000.0 in Q1 2022.
• Historically, Shares Outstanding has averaged $65.5 million across 5 years, with a median of $10000.0 in 2022.
• Annual changes were most pronounced in 2025 — Shares Outstanding tumbled 99.99% — and 2026, when it jumped 2039303.53%.
• Immunovant's Shares Outstanding stood at $129.3 million in 2022, then sank by 99.99% to $10000.0 in 2023, then changed by 0.0% to $10000.0 in 2024, then surged by 2033068.85% to $203.3 million in 2025, then rose by 0.31% to $203.9 million in 2026.
• The last three Shares Outstanding figures came in at $203.9 million (Q1 2026), $203.3 million (Q4 2025), and $10000.0 (Q3 2025), per Business Quant data.